Celon Pharma S.A. (WSE:CLN)

Market Cap	1.29B
Revenue (ttm)	215.11M
Net Income (ttm)	-43.86M
Shares Out	53.86M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	27.62
Dividend	0.08 (0.36%)
Ex-Dividend Date	Jun 27, 2024

Volume	1,561,048
Average Volume	92,406
Open	22.50
Previous Close	22.50
Day's Range	22.40 - 25.30
52-Week Range	15.46 - 32.90
Beta	0.83
RSI	62.64
Earnings Date	Sep 23, 2025

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 558
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2024, Celon Pharma's revenue was 204.98 million, a decrease of -4.18% compared to the previous year's 213.92 million. Losses were -34.45 million, 22.5% more than in 2023.